Skip to main content
Article
Assessment of the Fanconi anemia repair pathway as a predictor of clinical activity of pembrolizumab (PEM).
Journal of Clinical Oncology (2019)
  • Miguel Angel Villalona-Calero, Baptist Hospital of Miami
  • John Paul Diaz, Baptist Hospital of Miami
  • Zuanel Diaz, Baptist Hospital of Miami
  • Wenrui Duan, Florida International University
  • Eric Douglas Schroeder, Baptist Hospital of Miami
  • Santiago Aparo, Baptist Hospital of Miami
  • Troy Antony Gatcliffe, Baptist Hospital of Miami
  • Alfredo Pedro Alonso, Baptist Hospital of Miami
  • Sebastian Cuitiva, Baptist Hospital of Miami
  • Federico Albrecht, Baptist Hospital of Miami
  • Siddhartha A. Venkatappa, Baptist Hospital of Miami
  • Victor Guardiola, Baptist Hospital of Miami
  • Michael B. Troner, Baptist Hospital of Miami
  • Sara M. Garrido, Baptist Hospital of Miami
  • Gail Walker, Baptist Hospital of Miami
  • Muni Rubens, Baptist Hospital of Miami
  • Fernando I. De Zarraga, Baptist Hospital of Miami
  • Hao Vuong, Radiology Specialists of South Florida, Miami, FL;
Publication Date
May 20, 2019
DOI
10.1200/jco.2019.37.15_suppl.2555
Citation Information
Miguel Angel Villalona-Calero, John Paul Diaz, Zuanel Diaz, Wenrui Duan, et al.. "Assessment of the Fanconi anemia repair pathway as a predictor of clinical activity of pembrolizumab (PEM)." Journal of Clinical Oncology Vol. 37 (2019) p. 2555 - 2555
Available at: http://works.bepress.com/santiago-aparo/37/